Decheng Capital LLC — 13F Holdings & Portfolio
CIK 2010850 · latest 13F-HR filed 2026-08-14
Decheng Capital LLC manages $731.7M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGON (61.87%), NUVB (20.15%), AARD (3.08%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 9, and trimmed 3.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
BUILDING 2, SUITE 110
MENLO PARK, CA 94025
$731.7M
Long-equity book
14
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −1 / ↑9 / ↓3
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Nuvation Bio Inc.$36.1M +32.4%
- AARDVARK THERAPEUTICS INC$7.8M +52.8%
- Aclaris Therapeutics, Inc.$6.2M +41.1%
- Equillium Inc.$5.3M +60.0%
- Arcus Biosciences, Inc$4.0M +38.8%
Top Trims
- Upstream Bio Inc.-$5.7M -23.1%
- NEWAMSTERDAM PHARMA CO NV-$4.4M -42.4%
- Lyell Immunopharma, Inc.-$4.2M -30.0%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 156944100 | $452.7M | 61.87% | 6,371,669 | SH |
| 2 | Nuvation Bio Inc. | NUVB | 67080N101 | $147.4M | 20.15% | 25,954,439 | SH |
| 3 | AARDVARK THERAPEUTICS INC | AARD | 002942100 | $22.6M | 3.08% | 3,917,299 | SH |
| 4 | Aclaris Therapeutics, Inc. | ACRS | 00461U105 | $21.4M | 2.92% | 4,041,736 | SH |
| 5 | Upstream Bio Inc. | UPB | 91678A107 | $18.9M | 2.58% | 2,724,868 | SH |
| 6 | Arcus Biosciences, Inc | RCUS | 03969F109 | $14.3M | 1.96% | 464,779 | SH |
| 7 | Equillium Inc. | EQ | 29446K106 | $14.2M | 1.94% | 4,447,308 | SH |
| 8 | REVOLUTION MEDICINES INC(NSM) | RVMD | 76155X100 | $9.9M | 1.35% | 52,667 | SH |
| 9 | Lyell Immunopharma, Inc. | LYEL | 55083R104 | $9.7M | 1.33% | 692,050 | SH |
| 10 | BeyondSpring Inc. | BYSI | G10830100 | $6.7M | 0.91% | 3,800,702 | SH |
| 11 | Zentalis Pharmaceuticals Inc. | ZNTL | 98943L107 | $6.4M | 0.88% | 1,323,327 | SH |
| 12 | NEWAMSTERDAM PHARMA CO NV | NAMS | N62509109 | $6.0M | 0.82% | 176,887 | SH |
| 13 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 747324101 | $983.7K | 0.13% | 326,810 | SH |
| 14 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $625.2K | 0.09% | 20,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $731.7M | 14 | 0001104659-26-096837 |
| 2026-03-31 | 2026-05-13 | $661.3M | 14 | 0001104659-26-060145 |
| 2025-12-31 | 2026-02-12 | $743.4M | 19 | 0001104659-26-014146 |
| 2025-09-30 | 2025-11-14 | $573.2M | 23 | 0001104659-25-112117 |